Effects of oxycodone combined with dexmedetomidine in patients undergoing radical lung cancer surgery
LIN Lujing
ZENG Shenbao
LIN Kengqiang
Abstract：Objective To explore the effects of oxycodone combined with dexmedetomidine in patients undergo-ing radical lung cancer surgery.Methods A total of 120 patients who underwent radical lung cancer surgery at Fuzhou Pul-monary Hospital of Fujian between June 2018 and June 2024 were enrolled as the research objects and randomly divided into the oxycodone group(anesthesia with oxycodone combined with dexmedetomidine,n=60)and the propofol group(anesthesia with propofol combined with dexmedetomidine,n=60)according to random number table method.The immunosuppression(T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+ratio)),pain degree(Numerical Rating Scale(NRS)scores at different time points after operation in resting and active states),short-term cognitive function(Mini-Mental State Examination(MMSE)scores)and the incidence of adverse reactions were compared between the two groups.Results After surgery,levels of CD4+and CD4+/CD8+ratios in the oxycodone group were(38.42±3.32)%and(1.14±0.13),higher than those in the propofol group((33.84±3.56)%,(0.96±0.15))(t=7.288,7.027,both P＜0.05).The oxycodone group had a lower CD8+level((28.43±3.26)%)than the propofol group((32.54±3.57)%)(t=6.585,P＜0.05).At 12,24 and 48 h after surgery,NRS scores at resting and active states in the oxyco-done group were lower than those in the propofol group(F=10.975,8.374,both P＜0.05).At 6,24 and 48 h after surgery,MMSE scores in the oxycodone group were higher than those in the propofol group,with smaller fluctuations(F=3.501,P＜0.05).The incidence of adverse reactions was 6.67%(4/60)in the oxycodone group and 20.00%(12/60)in the propofol group,with a sta-tistically significant difference(χ2=4.615,P＜0.05).Conclusion Oxycodone combined with dexmedetomidine can alleviate im-munosuppression,reduce pain levels,and minimize fluctuations in short-term cognitive function in patients undergoing radical lung cancer surgery,with a favorable safety profile.
Keywords：oxycodonedexmedetomidineradical lung cancer surgeryimmunosuppressionshort-term cognitive function
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：4( 1551-1554 )